iBio, Inc. IBIO
Set alert
As of Nov 2, 10:52 AM ET
- YTD
- -59.85%
- 1 year
- -51.57%
- Open
- 0.80
- Prev close
- 0.7687
- Mkt cap
- 49.83M
- Vol
- 114.49K
- Avg vol
- 707.20K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7623
- High
- 0.80
- Forward P/E
- -1.44
- Beta
- 0.00
- Short ratio
- 1.92
- Inst. own
- 31.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2025
- 50-d avg
- 2.60
- 200-d avg
- 2.17
- 1y target
- 3.60
5D chart
Signals (128)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:25 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 6 days ago |
News
3 days ago benzinga.com
Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor
There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
-
2 weeks ago benzinga.com
iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human…
2 weeks ago globenewswire.com
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human…
1 month ago defenseworld.net
Squarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIO
Squarepoint Ops LLC acquired a new stake in iBio, Inc. (NASDAQ: IBIO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 498,872 shares of the…
1 month ago benzinga.com
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
-
1 month ago benzinga.com
HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
2 months ago globenewswire.com
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
2 months ago globenewswire.com
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
3 months ago globenewswire.com
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
-
4 months ago benzinga.com
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approachWhen combined with semaglutide, IBIO-610 drove…
4 months ago globenewswire.com
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
-
4 months ago benzinga.com
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.
5 months ago globenewswire.com
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary…
5 months ago globenewswire.com
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
5 months ago globenewswire.com
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with…
6 months ago globenewswire.com
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN…
7 months ago seekingalpha.com
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
7 months ago globenewswire.com
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
7 months ago globenewswire.com
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total…
8 months ago defenseworld.net
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies…
8 months ago globenewswire.com
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive…
8 months ago defenseworld.net
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on…
8 months ago globenewswire.com
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway
9 months ago zacks.com
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
9 months ago defenseworld.net
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
Vincerx Pharma (NASDAQ: VINC - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses…
9 months ago defenseworld.net
iBio (NYSEMKT:IBIO) Trading 8.3% Higher – Here’s Why
Shares of iBio, Inc. (NYSEMKT:IBIO - Get Free Report) traded up 8.3% during trading on Friday. The stock traded as high as $2.35 and last traded at $2.35. 1,928,910 shares were traded during trading,…
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings
1 year ago benzinga.com
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
1 year ago benzinga.com
This Kontoor Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
This Kontoor Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
1 year ago benzinga.com
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session